EGFR and neoplasm: In recent anti-cancer therapy, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, have been used as a powerful therapeutic strategy to block tumor growth by binding certain parts of EGFR and have improved the survival rates in tumor patients [10,11].